Anamnesis peculiarities of BRCA1-associated breast cancer in young women
https://doi.org/10.17650/1994-4098-2012-0-3-4-54-57
Abstract
A group of reproductive age patients whose disease is associated with the carriage of BRCA1 gene mutation is of scientific interest. Differences in the molecular pathogenesis between BRCA-associated breast cancer and sporadic counterpart might presuppose anamnesis features of each group as well. We have ascertained that the mean age in young age patients with positive BRCA1 status is 31.8 ± 3.3 years, in 40 % of cases in the family history in the 1st and 2 nd order relatives a breast cancer was identified, in 40 % of cases breast cancer was diagnosed during pregnancy, breast feeding or 1 year post-pregnancy, the disease course in young BRCA1-positive patients is characterized by a 30 % risk of contralateral breast cancer during the first 5 years of observation.
About the Authors
D. E. Avtomonov
Research Institute of Clinical Oncology N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. A. Parokonnaya
Research Institute of Clinical Oncology N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
L. N. Lyubchenko
Research Institute of Clinical Oncology N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
M. I. Nechushkin
Research Institute of Clinical Oncology N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
D. N. Kravchenko
Research Institute of Clinical Oncology N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Любченко Л.Н., Гарькавцева Р.Ф. ДНК-диагностика и медико-генетическое консультирование при наследственном раке молочной железы. Рак молочной железы. Под ред. Н.Е. Кушлинского, С.М. Портного, К.П. Лактионова. М.: Издательство РАМН, 2005. С. 198−209.
2. Федорова О.Е., Любченко Л.Н., Паяниди Ю.Г. и др. Использование био- чипов при изучении распространенных мутаций в генах BRCA 1/2 и CHEK 2 у больных органоспецифичным раком яичников и первично-множественными злокачественными новообразованиями с поражением яичников (российская популяция). Мол биол 2007;41(1): 37−42.
3. Breast Cancer Linkage Consortium. J Natl Cancer lst 1999;91:1310−6.
4. Breast Cancer Linkage Consortium. Familian Cancer 2003;2(3−4):18−32.
5. Cullinane C.A., Lynch H.T., Narod S.A. Effect of pregnancy as a risk factor for breast cancer in RCA1/BRCA2 mutation carriers. Int J Cancer 2005;20;117(6):988−91.
6. Dupont W., Page D. Risk faсtors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312: 146−51.
7. Friedman E., Kotsopoulos J., Lynch H.T., Rosen B. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 2006;8(2):15.
8. Fishman J., Fukushima D., Lynch H.T. et al. Plasma hormone profiles of young women at risk for familial breast cancer. Cancer Res 1978;38(2):4006−11.
9. Hampl M., Plaschke J., Burgemeister R. et al. Sequence analysis of BRCA1 gene in young breast cancer patients and/or positive family history. Langenbecks Arch Chir Suppl Kongressbd,1998. P. 267−72.
10. Jernstrom H., Lynch H.T., Narod S.A. Breast-feeding and the risk of breast cancer in BRCAl and BRCA2 mutation carriers. J Natl Cancer Inst 2004;21;96(14):1094−8.
11. Johannson O., Ranstam J., Borg A. et al. Sunital of BRCA 1 breast and ovarian cancer in patients: apopulation-based study from southem Suleden. J Clin Oncol 1998; 16(1):397−404.
12. Johnson S.M., Shaw J.A., Walker R.A. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. Int J Cancer 2002; 98(2):205−9.
13. Kotsopoulos J., Lubinski J., Lynch H.T., Narod S.A. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 2005;16(6):667−74.
14. Graeser M.K., Christoph E. Rhiemet K. et al. Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers? J Clin Oncol 2009;27(35):25−30.
15. McDonnell S., Schaid D., Myers J. et al. Efficacy of contralateral prophylactic mast- ectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001; 19:3938−43.
16. Rebbeck T., Friebel T., Lynch H. et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22(6):1055−62.
Review
For citations:
Avtomonov D.E., Parokonnaya A.A., Lyubchenko L.N., Nechushkin M.I., Kravchenko D.N. Anamnesis peculiarities of BRCA1-associated breast cancer in young women. Tumors of female reproductive system. 2012;(3-4):54-57. (In Russ.) https://doi.org/10.17650/1994-4098-2012-0-3-4-54-57
Views:
570
Email this article 